Screener Summaries Updates Institutions Sign In More Updates › Other Events › ELTX Other Events · Jun 17, 2026
Elicio Therapeutics, Inc. announced preliminary clinical observations supporting the evaluation of ELI-002 7P with… ELTX Elicio Therapeutics, Inc.
Elicio Therapeutics, Inc. announced preliminary clinical observations supporting the evaluation of ELI-002 7P with checkpoint inhibition and plans to conduct a Phase 1 study in first-line metastatic mutant KRAS pancreatic ductal adenocarcinoma, pending funding. Elicio Therapeutics, Inc. is a biotechnology company focused on developing immunotherapy treatments.
More from Elicio Therapeutics, Inc. Reports Q3 net loss of $0.30 per share and raises $4.3M via ATM program Nov 5, 2026 Elicio Therapeutics reported second quarter 2026 financial results, posting a net loss of $8.2 million ($0.43 per… Aug 13, 2026 Elicio Therapeutics, Inc. entered into a Securities Purchase Agreement on July 1, 2026, to issue and sell 4,380,313… Jul 2, 2026 Elicio Therapeutics, Inc. announced the results from its randomized Phase 2 AMPLIFY-7P study in adjuvant mutant… Jun 15, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
